Stock Forecast

  ImmuCell Corporation ( ICCC) Stock. Should you Buy or Sell?    $ 7.76

-0.09 (-1.17 %)



ImmuCell Corporation Analysis

Updated on 10-09-2022
Symbol ICCC
Price $7.76
Beta 0.584
Volume Avg. $9.27 thousand
Market Cap $60.12 M
52 Week Range $6.96 - $10.96


ImmuCell Corporation opened the day at $7.76 which is -1.17 % on yesterday's close. ImmuCell Corporation has a 52 week high of $10.96 and 52 week low of $6.96, which is a difference of $4. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $60.12 M and total net profit is $19243000 which means the company is trading at 3.12 times profit to market capitalization. Theoretically, if you were to buy ImmuCell Corporation for $60.12 M, it would take 15 years to get your money back. ImmuCell Corporation are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




ImmuCell Corporation Stock Forecast - Is ImmuCell Corporation a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio 194.000
Dividend Yiel 0.000
Net Profit Margin 0.013


Valuing ImmuCell Corporation


Price Book Value Ratio 1.834 Price To Book Ratio 1.834
Price To Sales Ratio 2.938 Price Earnings Ratio 219.380


How liquid is ImmuCell Corporation


Current Ratio 6.907
Quick Ratio 4.975


Debt


Debt Ratio 0.287 Debt Equity Ratio 0.403
Long Term Debt To Capitalization 0.246 Total Debt To Capitalization 0.264



Latest news about ImmuCell Corporation


ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2022 Results - Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC ) Q2 2022 Earnings Conference Call August 12, 2022 9:00 AM ET Company Participants Joe Diaz - Investor Relations Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas - MKH Management Operator Good morning. This is Anthony from Chorus Call and I will be assisting with our conference call this morning.

Date : 12/08/2022

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022

Conference Call Scheduled for Friday, August 12, 2022 at 9:00 AM ET Conference Call Scheduled for Friday, August 12, 2022 at 9:00 AM ET

Date : 04/08/2022

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2022 Results - Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC ) Q1 2022 Earnings Conference Call May 13, 2022 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Joseph Crabb - Former Chief Scientific Officer and VP Operator Good morning. This is Andrea from Chorus Call.

Date : 13/05/2022

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022

Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET

Date : 10/05/2022

ImmuCell Corp (ICCC) CEO Michael Brigham Q4 2021 Results Earnings Call Transcript

ImmuCell Corp (ICCC) CEO Michael Brigham Q4 2021 Results Earnings Call Transcript

Date : 23/02/2022





About ImmuCell Corporation


CEO : Mr. Michael Brigham
Sector : Healthcare
Industry : Biotechnology

Website : https://immucell.com

Exchange : NASDAQ Capital Market

Description :

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.


My Newsletter

Sign Up For Updates & Newsletters